Evidence map›Paper›PMID 38260577›Full record

ArticlebioRxiv : the preprint server for biology2024

Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairment.

Florian J Raabe, Anna Hausruckinger, Miriam Gagliardi, Ruhel Ahmad, Valeria Almeida, Sabrina Galinski, Anke Hoffmann, Liesa Weigert, Christine K Rummel, Vanessa Murek and 33 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 11 institutions in 5 countries.

Florian J RaabeLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Anna HausruckingerLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Miriam GagliardiDepartment of Psychiatry, University of Münster, 48149 Münster, Germany.
Ruhel AhmadLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Valeria AlmeidaDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Sabrina GalinskiDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Anke HoffmannDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Liesa WeigertLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Christine K RummelLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Vanessa MurekLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Lucia TrastullaLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Laura Jimenez-BarronLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Alessia AtellaDepartment of Psychiatry, University of Münster, 48149 Münster, Germany.
Susanne MaidlLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Danusa MenegazMax Planck Institute of Psychiatry, 80804 Munich, Germany.
Barbara HaugerMax Planck Institute of Psychiatry, 80804 Munich, Germany.
Eva-Maria WagnerMax Planck Institute of Psychiatry, 80804 Munich, Germany.
Nadia GabelliniDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Beate KauschatDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Sara RiccardoTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
Marcella CesanaTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
Sergi PapiolDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Vincenza SportelliDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Monika Rex-HaffnerDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Sebastian J StolteDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Michael C WehrDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Tatiana Oviedo SalcedoDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Irina PapazovaDepartment of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
Sevilla Detera-WadleighHuman Genetics Branch, National Institute of Mental Health Intramural Research Program (NIMH-IRP), Bethesda, MD, 20892, USA.
Francis J McMahonHuman Genetics Branch, National Institute of Mental Health Intramural Research Program (NIMH-IRP), Bethesda, MD, 20892, USA.
Andrea SchmittDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Peter FalkaiDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Alkomiet HasanDepartment of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
Davide CacchiarelliTelethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
Udo DannlowskiInstitute for Translational Psychiatry, University of Münster, 48149 Münster, Germany.
Igor NenadićDepartment of Psychiatry and Psychotherapy, Philipps-University and University Hospital Marburg, UKGM, 35039 Marburg, Germany.
Tilo KircherDepartment of Psychiatry and Psychotherapy, Philipps-University and University Hospital Marburg, UKGM, 35039 Marburg, Germany.
Volker ScheussDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Matthias EderMax Planck Institute of Psychiatry, 80804 Munich, Germany.
Elisabeth B BinderDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Dietmar SpenglerDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Moritz J RossnerDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
Michael J ZillerLab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
Max Planck Institute of Psychiatry · DELMU Klinikum · DEUniversity of Münster · DENational Institute of Mental Health · USPhilipps University of Marburg · DEUniversity of Augsburg · DEIstituto Universitario di Studi Superiori di Pavia · ITNext Generation Technology (United States) · USTelethon Institute Of Genetics And Medicine · ITUniversidade de São Paulo · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
Mapping genes that contribute to bipolar disorderZIAMH002810 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MCMAHON, FRANCIS J · 2009 to 2025
$31.2M
QUANTITATIVE ANALYSIS OF MICROVASCULAR CHANGES IN THE AGING BRAINP01AG002219 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HAROUTUNIAN, VAHRAM · 1985 to 2009
$19.2M
White Matter Abnormalities in SchizophreniaP50MH066392 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BUXBAUM, JOSEPH D. · 2002 to 2012
$18.6M
Project 5: In vivo measurement of GABA transmission in healthy controls & subjectP50MH084053 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 2008 to 2012
$11.5M
International Cohort Collection for Bipolar DisorderR01MH085542 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI SMOLLER, JORDAN W · 2008 to 2012
$10.7M
Cis-Regulatory Epigenome Mappings in SchizophreniaU01MH103392 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AKBARIAN, SCHAHRAM, SKLAR, PAMELA · 2014 to 2017
$7.6M
Molecular Profiling of SchizophreniaR01MH110921 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHESS, ANDREW J, ROUSSOS, PANAGIOTIS · 2016 to 2020
$6.9M
Genetics Association in Schizophrenia and Other DisordersR37MH057881 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEVLIN, BERNIE · 2013 to 2022
$5.4M
Risk genetic variants and cis regulation of gene expression in Bipolar DisorderR01MH109677 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROUSSOS, PANAGIOTIS · 2016 to 2020
$4.6M
Src mediates molecular alterations leading to NMDAR hypofunction in schizophreniaR01MH075916 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BORGMANN-WINTER, KARIN, HAHN, CHANG-GYU · 2006 to 2019
$3.3M
Integrated Multiscale Networks in SchizophreniaR01MH109897 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRENNAND, KRISTEN JENNIFER, ROUSSOS, PANAGIOTIS · 2016 to 2020
$3.0M
Intramural NIH HHS ZIA MH002810NIA NIH HHS P01 AG002219NIA NIH HHS P50 AG005138NIDA NIH HHS HHSN271201300031CNIMH NIH HHS P50 MH066392NIMH NIH HHS P50 MH084053NIMH NIH HHS R01 MH075916NIMH NIH HHS R01 MH080405NIMH NIH HHS R01 MH085542NIMH NIH HHS R01 MH093725NIMH NIH HHS R01 MH097276NIMH NIH HHS R01 MH109677NIMH NIH HHS R01 MH109897NIMH NIH HHS R01 MH110921NIMH NIH HHS R37 MH057881NIMH NIH HHS U01 MH103392
6 · The paper itself

Abstract

Schizophrenia (SCZ) is a genetically heterogenous psychiatric disorder of highly polygenic nature. Correlative evidence from genetic studies indicate that the aggregated effects of distinct genetic risk factor combinations found in each patient converge onto common molecular mechanisms. To prove this on a functional level, we employed a reductionistic cellular model system for polygenic risk by differentiating induced pluripotent stem cells (iPSCs) from 104 individuals with high polygenic risk load and controls into cortical glutamatergic neurons (iNs). Multi-omics profiling identified widespread differences in alternative polyadenylation (APA) in the 3' untranslated region of many synaptic transcripts between iNs from SCZ patients and healthy donors. On the cellular level, 3'APA was associated with a reduction in synaptic density of iNs. Importantly, differential APA was largely conserved between postmortem human prefrontal cortex from SCZ patients and healthy donors, and strongly enriched for transcripts related to synapse biology. 3'APA was highly correlated with SCZ polygenic risk and affected genes were significantly enriched for SCZ associated common genetic variation. Integrative functional genomic analysis identified the RNA binding protein and SCZ GWAS risk gene PTBP2 as a critical trans-acting factor mediating 3'APA of synaptic genes in SCZ subjects. Functional characterization of PTBP2 in iNs confirmed its key role in 3'APA of synaptic transcripts and regulation of synapse density. Jointly, our findings show that the aggregated effects of polygenic risk converge on 3'APA as one common molecular mechanism that underlies synaptic impairments in SCZ.

Identifiers

PMID38260577
PMCPMC10802452
OpenAlexW4390705966

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.